HansBiomed Full Year 2024 Earnings: ₩558 loss per share (vs ₩2,150 loss in FY 2023)

HansBiomed (KOSDAQ:042520) Full Year 2024 Results

Key Financial Results

• Revenue: ₩81.1b (up 4.0% from FY 2023).
• Net loss: ₩7.22b (loss narrowed by 69% from FY 2023).
• ₩558 loss per share (improved from ₩2,150 loss in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

HansBiomed shares are up 4.0% from a week ago.

Risk Analysis

You should learn about the 2 warning signs we've spotted with HansBiomed (including 1 which can't be ignored).

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.